



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts

Public declaration of interests

I, **MARIA JOSE TORRES JAEN**

Organisation/Company: HOSPITAL REGIONAL UNIVERSITARIO DE MALAGA, UNIVERSIDAD DE MALAGA, ESPAÑA

Country: Spain

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
01/2018-02/2018	Diater S.L.	Drug Hypersensitivity	
01/2019-02/2019	Aimmune Therapeutics	Drug hypersensitivity	
01/2020-02/2020	Leti Laboratories	Airway allergy	

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
01/2018-02/2018	GSK	Airway allergy	
03/2018-04/2018	Astra-Zeneca	Airway allergy	
03/2019-04/2019	Merck	Airway allergy	
03/2020-04/2020	Allergy Therapeutics	Airway allergy	
06/2020-07/2020	Bial Respiratorio	Airway allergy	

2.4 Financial interests

Classified as public by the European Medicines Agency

No interest declared

## 2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
02/2019-05/2019	Merck	SUBCUTANEOUS IMMUNOTHERAPY	RHINITIS AND ASTHMA
05/2016-07/2019	Novartis	QGE031	CHRONIC SPONTANEOUS URTICARIA
12/2017-(current)	ALK-ABELLO	SERUM POLL	ALLERGY DIAGNOSIS
11/2020-(current)	IMMUNOTEK SL	SUBCUTANEOUS ALLERGEN IMMUNOTHERAPY	ALLERGIC ASTHMA
01/2020-(current)	GSK	GSK3511294	EOSINOPHILIC ASTHMA
01/2020-(current)	GSK	GSK3511294, MEPOLIZUMAB, BENRALIZUMAB	EOSINOPHILIC ASTHMA

## 2.6 Investigator

Period	Company	Products	Therapeutic Indication
02/2019-05/2019	MERCK	SUBCUTANEOUS IMMUNOTHERAPY	ALLERGIC ASTHMA
01/2016-05/2016	NOVARTIS	QGE031	CHRONIC SPONTANEOUS URTICARIA
10/2017-(current)	ASTRA ZENECA	OBSERVATIONAL	COPD AND ASTHMA
10/2017-12/2019	NOVARTIS	QAW039	ASTHMA
04/2019-01/2020	NOVARTIS	QAW039	ASTHMA
04/2018-08/2020	ASTRA ZENECA	BENRALIZUMAB	ASTHMA
11/2018-(current)	NOVARTIS	LIGELIZUMAB	CHRONIC SPONTANEOUS URTICARIA
06/2020-(current)	NOVARTIS	LIGELIZUMAB	CHRONIC SPONTANEOUS URTICARIA
09/2020-(current)	ROXAL MEDICINA ESPAÑA	SUBLINGUAL IMMUNOTHERAPY	ALLERGIC RHINITIS
12/2020-(current)	ALLERGY THERAPEUTICS	SUBCUTANEOUS IMMUNOTHERAPY	HYMENOPTERA VENOM HYPERSENSITIVITY

## 2.7 Grant / Funding to organisation /institution

Company	Subject Matter
CONSORTIUM OF COMPANIES IN THE CONTEXT OF AN EU FUNDED PROJECT	EUROIMMUN PROJECT

3

## 2.8 Close family member interest

No interest declared

## 2.9 Repurposing of a medicinal product

No interest declared

## 2.10 Any other interests or facts

CLINICAL TRIAL WITH SUBCUTANEOUS IMMUNOTHERAPY WITH PRUP3 EXTRACT FOR LTP SYNDROME OF SEVERE PHENOTYPE (FUNDED BY INSTITUTO DE SALUD CARLOS III AND INVOLVING ALK-ABELLO PRODUCT).

PANEL REVIEWER OF PUBLIC RESEARCH CALLS: EUROPEAN COMMISSION, MINNECO AND INSTITUTO DE SALUD CARLOS III

MEMBER OF THE EXECUTIVE COMMITTEE OF EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY

## 2.11 CAT member or alternate

No interest declared

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result

Classified as public by the European Medicines Agency

of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	MARIA JOSE TORRES JAEN
Date:	2021-01-27

*For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template*